CalciMedica Bolsters Board with Appointment of Dr. Alan Glicklich
Generated by AI AgentMarcus Lee
Tuesday, Jan 14, 2025 7:13 am ET1min read
CALC--
CalciMedica, Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, has announced the appointment of Dr. Alan Glicklich to its Board of Directors, effective January 15, 2025. Dr. Glicklich, currently serving as Chief Medical Officer of Nuvig Therapeutics, brings over 20 years of biotechnology industry experience to CalciMedica, with a strong background in inflammatory and immunologic disease spaces.
Dr. Glicklich's extensive experience in clinical development, including leadership roles at Chinook Therapeutics, Bird Rock Bio, and Arena Pharmaceuticals, will be invaluable to CalciMedica as it progresses its lead product candidate, Auxora, towards Phase 3 trials in acute pancreatitis and awaits data from the KOURAGE trial in acute kidney injury. His expertise in inflammatory and immunologic diseases will also contribute to CalciMedica's ongoing clinical trials and pipeline development.
Dr. Glicklich's appointment strengthens CalciMedica's expertise in inflammatory and immunologic disease spaces, which will be crucial in advancing Auxora and other potential therapies through clinical trials and towards regulatory approval. His leadership and strategic guidance will be instrumental in CalciMedica's future drug development strategies, ensuring that the company remains at the forefront of innovative therapies for life-threatening inflammatory and immunologic diseases.
In conclusion, CalciMedica's appointment of Dr. Alan Glicklich to its Board of Directors is a strategic move that will significantly contribute to the company's ongoing clinical trials and pipeline development. Dr. Glicklich's expertise in inflammatory and immunologic diseases, coupled with his leadership in clinical development, will be invaluable in advancing CalciMedica's mission to develop therapies for critically ill patients whose needs are unmet by current therapies.
CHRO--
CalciMedica, Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, has announced the appointment of Dr. Alan Glicklich to its Board of Directors, effective January 15, 2025. Dr. Glicklich, currently serving as Chief Medical Officer of Nuvig Therapeutics, brings over 20 years of biotechnology industry experience to CalciMedica, with a strong background in inflammatory and immunologic disease spaces.
Dr. Glicklich's extensive experience in clinical development, including leadership roles at Chinook Therapeutics, Bird Rock Bio, and Arena Pharmaceuticals, will be invaluable to CalciMedica as it progresses its lead product candidate, Auxora, towards Phase 3 trials in acute pancreatitis and awaits data from the KOURAGE trial in acute kidney injury. His expertise in inflammatory and immunologic diseases will also contribute to CalciMedica's ongoing clinical trials and pipeline development.
Dr. Glicklich's appointment strengthens CalciMedica's expertise in inflammatory and immunologic disease spaces, which will be crucial in advancing Auxora and other potential therapies through clinical trials and towards regulatory approval. His leadership and strategic guidance will be instrumental in CalciMedica's future drug development strategies, ensuring that the company remains at the forefront of innovative therapies for life-threatening inflammatory and immunologic diseases.
In conclusion, CalciMedica's appointment of Dr. Alan Glicklich to its Board of Directors is a strategic move that will significantly contribute to the company's ongoing clinical trials and pipeline development. Dr. Glicklich's expertise in inflammatory and immunologic diseases, coupled with his leadership in clinical development, will be invaluable in advancing CalciMedica's mission to develop therapies for critically ill patients whose needs are unmet by current therapies.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet